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1  Introduction 
Erectile dysfunction (ED) and coronary artery disease 
(CAD) are closely linked, as both conditions share the same 
cardiovascular risk factors.[1] Indeed, these risk factors can 
determine endothelial dysfunction that represents the com-
mon underlying mechanism of both ED and CAD.[1,2]  
The prevalence of ED is about three-fold higher among 
diabetic patients than in the general population[1,3] and a 
higher prevalence of CAD has been observed in people with 
diabetes when compared to non-diabetic subjects.[3] Some 
studies showed that ED can be a powerful marker of silent 
CAD[4,5] and a strong predictor of cardiovascular events in 
apparently uncomplicated type 2 diabetic patients.[6,7] 
Therefore ED is now considered as a sentinel symptom of 
silent CAD, as ED often precedes the onset of myocardial 
ischemia itself by many years.[2,8,9]   
Silent CAD can worse the prognosis of diabetic patients 
and this suggests to identify diabetic patients at higher risk 
for silent CAD in order to early and effectively treat 
them.[1013] Current guidelines suggest the screening for 
CAD when diabetic patients have some clinical conditions 
or at least two cardiovascular risk factors in addition to dia-
betes.[14] Unfortunately several studies showed that about 
40% of diabetic patients with silent CAD can be missed on 
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the basis of the current guidelines,[15,16] but ED may inter-
estingly improve sensitivity and specificity of guidelines for 
CAD screening when it is added to the common cardiovas-
cular risk factors.[16] 
ED is the most frequently diagnosed sexual dysfunction 
in the older male population, especially after 70 years, even 
if it is often underreported and under-diagnosed in the eld-
erly.[17] In addition, CAD prevalence increases with age. So 
it may be of great interest to understand whether ED re-
mains a risk factor for silent CAD in elderly diabetic pa-
tients. To the best of our knowledge, no study has specifi-
cally investigated the role of ED as a predictor of silent 
CAD in type 2 diabetic elderly subjects. Therefore, the aim 
of the present study was to evaluate whether ED may be a 
marker of asymptomatic CAD also in elderly patients with 
diabetes. 
2  Methods 
A population of 328 consecutive males with type 2 dia-
betes mellitus were enrolled in this study. All the patients 
attending at the outpatient diabetic clinic for the first time 
were recruited. Exclusion criteria were: type 1 diabetes mel-
litus, decreased C-peptide, positive anti-GAD antibodies, 
limited life-expectancy, any chronic or acute disease, ma-
lignancies, any known or suspect cardiovascular disease, 
such as history of coronary events or artery revasculariza-
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tion, heart failure, abnormal resting ECG suggestive of 
myocardial ischemia or infarction, uncontrolled hyperten-
sion (> 180/100 mmHg), atrial fibrillation or other impor-
tant arrhythmias, significant valvular diseases, cardiomyo-
pathy, previous stroke, claudicatio intermittens. 
To assess the presence of asymptomatic CAD an exercise 
stress testing was performed in all the subjects; alternatively 
a dipyridamole stress testing was performed in people with 
any condition that did not permit maximal exercise testing 
(such as severe obesity, foot wound, and so on) or in those 
with inconclusive exercise stress testing. Procedures for 
exercise stress testing and dipyridamole stress testing and 
criteria for the diagnosis of asymptomatic CAD were re-
ported elsewhere.[4,16] In patients with a positive noninvasive 
testing for CAD a coronary angiography was proposed. 
Angiography was performed as previously described.[18] A 
coronary lesion was considered significant when a stenosis 
≥ 50% of the lumen was observed.  
All criteria for the diagnosis of type 2 diabetes, hyperten-
sion, dyslipidemia, presence of micro and macroalbuminu-
ria, smoking habits, family history of CAD were previously 
reported.[4,6,11]  
Venous blood samples were taken from the patients after 
fasting for at least 12 h. Cholesterol, high-density lipopro-
tein (HDL) and triglycerides were measured by an auto-
matic analyzer HITACHI 737 (Tokio, Japan). Low-density 
lipoprotein (LDL) was estimated by the Friedewald’s for-
mula.[19] Albumin excretion rate (AER) was assessed by 
nephelometry (Beckmann, Milan, Italy). Glycated hemo-
globin (HbA1c) was measured by high-performance liquid 
chromatography (Biorad, Richmond,  USA). 
The presence of ED was assessed by the validated Inter-
national Index Erectile Function-5 (IIEF-5) questionnaire.[20] 
ED was defined as an IIEF-5 score < 21.[20] 
The study was approved by the local ethics committee. 
All patients gave their informed consent both to participate 
in the investigation and to perform each test. 
Univariate analysis was performed with Student t-test to 
assess differences in normally distributed variables, while 
Mann-Whitney U-test was used in non-normally distributed 
parameters. The Pearson Chi-squared test was used for fre-
quency comparison. The following variables were tested as 
potential predictors of silent CAD in a multiple logistic re-
gression analysis: body mass index, HbA1c, total choles-
terol, LDL-cholesterol, HDL-cholesterol, triglycerides, mi-
cro/macroalbuminuria, smoking, family history of CAD, 
hypertension and ED. Variables were dichotomized as pre-
viously reported.[4,6,11] A P value < 0.05 was considered 
statistically significant. 
3  Results  
The study population of 328 men was divided by age into 
two groups: 213 subjects were aged ≤ 65 years (Group A) 
and 115 men were older than 65 years (Group B). Each 
group was stratified by the presence/absence of asympto-
matic CAD angiographically proven. 
Table 1 shows clinical and biochemical features of the 
Group A stratified by presence/absence of CAD. As shown, 
younger diabetic patients with silent CAD have a significant 
greater prevalence of micro/macroalbuminuria, smokers, 
family history for CAD and ED than those without silent 
CAD. 
Table 2 shows clinical and biochemical features of the 
Group B stratified by presence/absence of CAD. As shown, 
older diabetic patients with silent CAD have a significant 
greater prevalence of micro/macroalbuminuria, smokers and 
family history for CAD than those without silent CAD. 
There is no significant difference in the prevalence of ED 
between patients with and those without silent CAD among 
older patients.  
Both among younger and older patients a multivariate 
Cox logistic regression analysis was performed with pres-
ence/absence of silent CAD as the dependent variable. In 
the GROUP A the analysis showed that smoking habits 
Table 1.  Features of the male patients aged between 45 and 
65 years stratified by presence/absence of CAD.  




n 213 45 168  
Age, yrs 56.6  5.7 55.7  5.0 57.0  6.1 0.101
BMI, kg/m2 28.4  3.8 27.6  3.7 28.7  3.5 0.119
HbA1c,% 8.1  1.2 8.0  1.3 8.2  1.1 0.277
Cholesterol, 
mg/dL 
207.0  29.5 213.1  29.1 203.1  28.6 0.011
LDL, mg/dL 128.4  30.0 132.1  30.1 124.4  29.9 0.065
HDL, mg/dL 44.8  8.8 44.2  7.9 45.2  8.9 0.578
Triglycerides, 
mg/dL 
165.1  66.6 186.3  73.9 162.8  61.8 0.059
Micro/Macroalbu-
minuria, % 
21.1 46.6 14.2 < 0.001
Smokers, % 26.2 68.8 14.8 < 0.001
Family history of 
CAD, % 
24.4 33.3 5.4 < 0.001
Hypertension*, % 58.2 55.5 58.9 0.683
ED, % 19.7 31.1 16.6 0.030
Data are presented as mean  SD unless other indicated. *Defined according 
to the current criteria of screening guidelines or in presence of specific treat-
ment. BMI: body mass index; CAD: coronary artery disease; ED: erectile 
dysfunction; HbA1c: haemoglobin; HDL: high-density lipoprotein; LDL: 
low-density lipoprotein. 
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Table 2.  Features of the male patients aged between 66 and 
75 years stratified by presence/absence of CAD. 




n 115 37 78  
Age, yrs 69.6  2.8 70.0  2.9 69.3  2.6 0.253
BMI, kg/m2 28.1  3.8 28.0  3.8 28.2  3.9 0.751
HbA1c, % 8.6  1.3 8.8  1.3 8.5  1.2 0.174
Cholesterol, mg/dL 203.0  29.0 205.9  29.1 201.2  28.8 0.251
LDL, mg/dL 122.1  28.9 124.2  30.1 121.8  27.9 0.189
HDL, mg/dL 44.2  8.4 44.0  8.0 45.3  8.5 0.711
Triglycerides, mg/dL 159.7  55.1 163.1  64.9 153.3  61.2 0.391
Micro/Macroalbu-
minuria, % 
25.2 51.3 12.8 < 0.001
Smokers, % 21.7 51.3 7.8 < 0.001
Family history of  
CAD, % 
20.0 43.3 6.4 <0.001
Hypertension*, % 71.3 67.5 73.1 0.231
ED, % 42.6 48.6 39.7 0.364
Data are presented as mean  SD unless other indicated.*Defined according 
to the current criteria of screening guidelines or in presence of specific treat-
ment. BMI: body mass index; CAD: coronary artery disease; ED: erectile 
dysfunction; HbA1c: haemoglobin; HDL: high-density lipoprotein; LDL: 
low-density lipoprotein. 
 
(OR: 8.51; 95% CI: 4.1116.47; P < 0.001), micro/ma-
croalbuminuria (OR: 6.11; 95% CI: 3.4614.61; P < 0.001), 
family history of CAD (OR: 2.9; 95% CI: 1.296.45; P = 
0.007) and ED (OR: 1.87; 95% CI: 1.027.31; P = 0.046) 
were significant predictors of silent CAD. In the Group B 
the analysis showed that microalbuminuria (OR: 5.78; 95% 
CI: 2.1312.97; P < 0.001) and smoking habits (OR: 2.65; 
95% CI: 2.136.21; P = 0.004) were significant predictors 
of silent CAD. ED does not enter the model. 
4  Discussion 
Previous studies showed that ED can be a powerful 
marker of asymptomatic CAD,[14,16] and that it may sig-
nificantly increase sensitivity and specificity of the current 
guidelines on the screening of CAD in diabetes.[16] The pre-
sent investigation shows that ED can be an useful tool to 
better identify subjects to screen for CAD among younger 
but not among older type 2 diabetic patients. Indeed, our 
data confirm the strong independent association between 
ED and silent CAD only in subjects aged 65 years or 
younger, but no association was observed in older patients 
both in univariate and multivariate analysis. This novel 
finding may be due to several reasons. As it is well-known, 
the prevalence of ED increases with age and this is caused 
by many factors in addition to vascular impairment.[21] 
Hormonal changes are usually observed in elderly people 
and they can play a major role in the occurrence of ED.[22] 
The Massachusetts Male Aging Study demonstrated that 
testosterone declines at a rate of 1%2% a year.[23] Free 
testosterone levels are reduced up to 30% in the 7th decade. 
Sex hormone binding globulin binds a higher percentage of 
total testosterone, up to 75%, reducing the amount of 
bio-available androgen. Luteinizing hormone is higher in 
the elderly, suggesting secondary hypogonadism.[23] Other 
conditions are able to increase the occurrence of ED inde-
pendently of vascular damage Among them, an important 
role is played by lower urinary tract symptoms (LUTS) and 
benign prostatic hyperplasia (BPH) that are very common in 
elderly subjects.[24] In addition many co-morbidities, in-
cluding hypertension, and their treatments are more frequent 
in older than in younger patients and they can favor the de-
velopment of ED also in subjects without significant vascu-
lar disease.[1,21] All these conditions can greatly affect the 
predictive power of ED for silent CAD in elderly people 
and this may explain our data.  
Silent CAD is a frequent complication in diabetes, but 
conflicting data are available in the literature on the poten-
tial effects of a systematic screening for unknown on the 
prognosis. Two large randomized controlled studies have 
shown that a systematic screening for CAD does not im-
prove the cardiovascular prognosis in diabetic subjects,[25,26] 
even if other work found opposite conclusions.[11,27] How-
ever, at the moment a systematic screening for CAD is not 
recommended,[13] but additional data are considered to be 
necessary.[1013]  
It is interesting to note that current guidelines for CAD 
screening may have their best predictive power in diabetic 
patients aged 60 years or more.[28] Our data suggest that ED 
may further increase the predictive power of current guide-
lines to identify who to screen for occult CAD among 
younger people with diabetes, even if ED seems to have no 
importance in older patients. However, the systematic as-
sessment of ED remains important in all people with diabe-
tes, since it permits not only to better stratify the individual 
cardiovascular risk but also to improve the quality of life.[29] 
To better estimate the risk for silent CAD in elderly diabetic 
patients, other risk factors may be evaluated, such as genetic 
risk factors,[3032] diabetic retinopathy,[33] disautonomic 
neuropathy.[15] At last, it is important to remember that pe-
ripheral artery disease is considered a strong predictor for 
CAD,[14] but this condition is often underdiagnosed.[34] 
Even if our study for the first time has shown the de-
creased predictive power of ED in the identification of silent 
CAD in elderly subjects with diabetes, it has some limita-
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tions. First, we do not have data on hormone profile, LUTS 
and BPH that may help to understand the reasons for our 
results. Second, the study population may be relatively 
small. Therefore larger studies should confirm our findings. 
In conclusion, the present study first suggests that ED 
seems to be not associated with silent CAD in type 2 dia-
betic patients aged 66 years or older and thus it may lose the 
important role of marker of occult CAD in the elderly dia-
betic population. However our data confirm that ED is a 
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